The 2024 International Consensus Reference Standard for Urinary Tract Infection (UTI) Research fails in Neurogenic Bladder without UTI symptoms

When the Gold Standard Fails the Patient

Diagnosing a urinary tract infection (UTI) typically relies on a clear signal. A patient feels pain, and their urine contains bacteria and white blood cells. However, for individuals living with neurogenic lower urinary tract dysfunction (NLUTD)—a condition where the bladder does not function normally due to nerve damage—this signal is fundamentally altered. In these populations, the body frequently maintains a baseline of bacteria (bacteriuria) and white blood cells (pyuria) in the urine without an actual infection.

Until recently, the medical community sought to resolve this ambiguity through a high-level consensus. In 2024, an international multidisciplinary group published a new "reference standard" intended to provide a universal framework for UTI research. The goal was to create a scoring system to distinguish true infection from harmless colonization. But a new study reveals a critical flaw. This new standard fails in specific populations, misclassifying a large proportion of asymptomatic patients as having "probable" infections.

The mismatch between consensus and biology

The core problem lies in a fundamental assumption. The framework assumes that certain urinary markers are reliable indicators of pathology. In neurologically intact individuals, the presence of white blood cells (pyuria) and specific bacteria in a urine culture is a strong proxy for infection. However, for those with spinal cord injuries (SCI/D) who use intermittent catheterization (IC) to manage their bladder, these markers represent a shifted biological baseline.

Current clinical practice often struggles with this distinction. This struggle leads to a cycle of systematic misdiagnosis. When clinicians treat asymptomatic bacteriuria (the presence of bacteria without symptoms) as an active infection, it triggers unnecessary antibiotic prescriptions. This contributes to antimicrobial resistance and leads to avoidable hospitalizations. The gap identified by the researchers is a failure of practice. Even as recent international standards acknowledged that these populations require specialized approaches, they nonetheless codified diagnostic assumptions that contradict the actual biology of the patients.

How the Bilsen scoring system functions

To understand why the standard fails, one must look at its architectural design. The 2024 Bilsen et al. framework operates as a weighted scoring algorithm across four distinct domains. A researcher applies the criteria to a sample and sums the points to assign a classification:

1. Symptoms and Signs (0–3 points): This tracks physical manifestations. The framework grants one automatic point to patients with spinal cord injuries. This acknowledges their potential inability to perceive or express traditional symptoms.
2. Systemic Criteria (0–2 points): This looks for evidence of whole-body involvement. Examples include fever or elevated inflammatory markers in the blood, such as C-reactive protein (a protein that increases during inflammation) or procalcitonin.
3. Pyuria (0–3 points): This measures the concentration of white blood cells (WBCs) in the urine. Higher concentrations yield higher points.
4. Culture (0–3 points): This evaluates the types of bacteria grown in a lab. Typical uropathogens (common infection-causing bacteria like E. coli) earn the maximum points.

The classification thresholds are fixed. A score of 0–2 is "No UTI." A score of 3–4 is "Possible UTI." A score of 5–7 is "Probable UTI." A score of $\ge$8 is "Definite UTI." For a population with a non-standard baseline, this scoring mechanism creates significant errors.

Quantifying the misclassification rate

The researchers tested this framework using 224 urine samples from 99 adults with NLUTD due to SCI/D. Every participant was verified as completely asymptomatic using the USQNB-IC (a validated questionnaire specifically designed for neurogenic bladder symptoms).

The results demonstrate a failure to identify "No UTI" cases. The researchers applied two ways to interpret the boundaries of the white blood cell categories. These findings were stark:

• Under a conservative interpretation: Only 40.2% of the asymptomatic samples were correctly classified as "No UTI." This means nearly 60% of healthy samples were misclassified. Meanwhile, 37.9% were flagged as "Probable UTI."
• Under an inclusive interpretation: The failure was even more pronounced. Only 11.6% of the samples were classified as "No UTI." An overwhelming 50.0% of these healthy samples were labeled "Probable UTI."

No sample reached the "Definite UTI" threshold. This was a structural consequence of the design. The "Systemic Criteria" domain scored zero for every participant. Since the patients were asymptomatic and no blood markers were drawn, they could not accumulate the high points required for a definite diagnosis. The researchers emphasize that these results are a "floor" estimate. If blood markers had been included, the scores would likely have risen. This would potentially increase the rate of misdiagnosis even further.

Structural failures and inherent limitations

The misclassification is a structural consequence of the framework's design. The Bilsen standard automatically awards one point for the neurological condition. It also heavily weights pyuria and culture. Consequently, any asymptomatic patient with baseline white blood cells or common uropathogens is mathematically pushed into the "Possible" or "Probable" categories. This happens before an actual infection is even considered.

Two caveats exist regarding this study's findings. First, the systemic domain was empty because the study protocol did not include drawing blood. This makes the reported misclassification rates a conservative estimate. However, it reflects the reality of routine clinical care for community-dwelling patients. Such invasive tests are rarely performed for suspected UTIs in daily practice. Second, the study focuses on those using intermittent catheterization. While the authors suggest the problem extends to other forms of neurogenic bladder, the specific dynamics of catheter-associated environments may influence the baseline presence of bacteria.

The verdict: A call for population-specific standards

The evidence suggests the 2024 international reference standard is unsuitable for the SCI/D population. It attempts to apply a tool calibrated for neurologically intact adults to a population with a distinct biological "normal." Using this standard in clinical research risks institutionalizing misdiagnoses.

The solution is to use standards that respect biological reality. The authors point to an existing alternative: the cUTI likelihood profiling approach. Unlike the Bilsen standard, this method prioritizes patient-reported symptoms. It uses validated tools like the USQNB as the primary diagnostic signal. This approach moves away from the flawed reliance on urinary markers that are inherently uninformative in this cohort. For researchers and clinicians working with neurogenic bladder, the priority is to utilize standards validated for the specific population being treated.